TBIO - Telesis Bio, Inc. Market Capitalization

Telesis Bio, Inc. (TBIO) is a pioneer in benchtop biomaterial synthesis that developed the unique BioXp system for rapid gene printing, accelerating medical research and development. This chart reflects an asset value of 0.01, while a capital shortfall complicates the struggle for market share against equipment manufacturing behemoths. The company's revenue is based on the sale of automated RNA and DNA synthesis systems to pharmaceutical giants and research centers.

TBIO telesisbio.com: Market Value in the range 04/28/2023 - 10/05/2024

Telesis Bio, Inc - analytical breakdowns and key metrics (TBIO)

- current price and projected stock value:

Stock Price Telesis Bio|TBIO - Price Target Chart

- market capitalization statistics:

Market Capitalization Telesis Bio, Inc|TBIO - Company Buyout Price

- issuer book value statistics:

Net Assets per Single Share Telesis Bio|TBIO - Total Stockholders' Equity|Market Capitalization to Book Value Ratio telesisbio.com|TBIO - Total Business Assets

- company liabilities and liquidity data:

- business earnings and investment ratios data:

TBIO - Company Net Income|Projected Future Earnings Telesis Bio, Inc.|TBIO - Market Cap to Earnings|Future Price to Earnings Codex DNA|TBIO - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Telesis Bio, Inc|TBIO - Operating income before deduction of amortization|Earnings per share for the last twelve months Telesis Bio|TBIO - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months telesisbio.com|TBIO - Earnings per share increase in current year|Earnings growth forecast for next year Telesis Bio, Inc.

Fundamental company analysis:Telesis Bio (TBIO)

Professional capital evaluates the issuer's profile through the lens of its market capitalization. This indicator captures the total value of all shares at the closing price, determining the scale of the business and its liquidity. By analyzing the aggregate value of the company's shares, an investor can see the amplitude of the asset's valuation fluctuations. For Telesis Bio, Inc. (TBIO), volatility is amplified due to export restrictions on DNA synthesis technologies, rendering the asset high-risk amid geopolitical fragmentation.

Competing companies